Foresite Capital

Activity from announced rounds

Activity in this selectionOct 17, 2026 · Jul 20, 2026

Foresite Capital is a healthcare investment firm identified by Abcuro and in its own Thyme Care portfolio record.

Recorded funding activity

Abcuro develops immunotherapies targeting pathogenic cytotoxic T cells. Thyme Care combines oncology care teams with technology, while Khartis develops oral medicines for immune and chronic diseases. The company histories distinguish care delivery from experimental drug development.

Sources
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$116M
2 disclosed · full round size, not this investor’s share

By stage

Series C+2
Series B1

By primary sector

Biotech2
Healthtech1

By country

United States3

Rounds

3 in this selection
Thyme Care

Thyme Care combines oncology-trained care teams and technology to support people through cancer treatment while helping health plans and providers improve outcomes and control costs. It monitors patient needs between appointments, coordinates with oncologists and connects members to clinical, practical and social support.

>$125MSeries E
Participant
Abcuro

Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.

$66MSeries D
Role not disclosed
Khartis Therapeutics

Develops oral small molecule therapies for immunological and chronic diseases

$50MSeries B
Role not disclosed